Clinical Study
Single High Intensity Focused Ultrasound Session as a Whole Gland Primary Treatment for Clinically Localized Prostate Cancer: 10-Year Outcomes
Table 3
Univariate and multivariable analysis of factors affecting biochemical recurrence free survival in 108 patients.
| | Univariate | Multivariate | | OR | 95% CI | value | OR | 95% CI | value |
| Age (per 10 years) |
0.95 | 0.51–1.76 | 0.87 | — | — | — | Gleason score (<7; ≥7) | 2.01 | 1.15–3.51 | 0.01 | 1.79 | 1.04–3.08 | 0.01 | Prostate volume (per 10 mL) | 1.29 | 0.74–2.22 | 0.37 | — | — | — | Pretherapeutic PSA (per ng/mL) | 1.06 | 1.04–1.09 | <0.0001 | 1.08 | 1.05–1.11 | <0.0001 | PSA nadir (per ng/mL) | 1.92 | 1.58–2.33 | <0.0001 | 1.87 | 1.54–2.27 | <0.0001 | ADT before HIFU (yes v/s no) | 1.56 | 0.92–2.62 | 0.1 | — | — | — | D'Amico risk group (low v/s intermediate) | 1.64 | 0.83–3.24 | 0.15 | — | — | — | D'Amico risk group (low v/s high) | 3.36 | 1.61–7.03 | 0.001 | 2.9 | 1.43–5.89 | 0.003 |
|
|
OR: odds ratio; CI: confidence interval; PSA: prostate-specific antigen; ADT: androgen deprivation therapy; HIFU: high intensity focused ultrasound.
|